Clinical Consequences of Cardiomyopathy in Children With Biliary Atresia Requiring Liver Transplantation

Noelle M. Gorgis, Curtis Kennedy, Fong Lam, Kathleen Thompson, Jorge Coss‐Bu, Ayse Akcan Arikan, Trung Nguyen, Kathleen Hosek, Tamir Miloh, Saul J. Karpen, Daniel J. Penny, John Goss, Moreshwar S. Desai – 3 August 2018 – Cirrhotic cardiomyopathy (CCM), a comorbidity of end‐stage cirrhotic liver disease, remains uncharacterized in children, largely because of a lack of an established pediatric definition.

Clinical Consequences of Cardiomyopathy in Children With Biliary Atresia Requiring Liver Transplantation

Noelle M. Gorgis, Curtis Kennedy, Fong Lam, Kathleen Thompson, Jorge Coss‐Bu, Ayse Akcan Arikan, Trung Nguyen, Kathleen Hosek, Tamir Miloh, Saul J. Karpen, Daniel J. Penny, John Goss, Moreshwar S. Desai – 3 August 2018 – Cirrhotic cardiomyopathy (CCM), a comorbidity of end‐stage cirrhotic liver disease, remains uncharacterized in children, largely because of a lack of an established pediatric definition.

Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure

Vinod Arora, Rakhi Maiwall, Vijayaraghavan Rajan, Ankur Jindal, Saggere Muralikrishna Shasthry, Guresh Kumar, Priyanka Jain, Shiv Kumar Sarin – 3 August 2018 – Hepatorenal syndrome (HRS) carries a high short‐term mortality in patients with cirrhosis and acute on chronic liver failure (ACLF). Terlipressin and noradrenaline are routinely used in cirrhosis with HRS and have been found to be equally effective. There are no data comparing the efficacy of terlipressin with noradrenaline in ACLF patients with HRS.

Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region

Chiao‐Ling Li, Chen‐Yu Li, You‐Yu Lin, Ming‐Chih Ho, Ding‐Shinn Chen, Pei‐Jer Chen, Shiou‐Hwei Yeh – 2 August 2018 – The gender disparity of hepatocellular carcinoma (HCC) is most striking in hepatitis B virus (HBV)‐related cases. The majority of such HCC cases contain integrated HBV, and some hotspot integrations, such as those in the telomerase reverse transcriptase gene (TERT) promoter, activate gene expression to drive carcinogenesis.

Global DNA 5‐Hydroxymethylcytosine and 5‐Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma

Jiao Liu, Jinhua Jiang, Jiezhen Mo, Dan Liu, Dan Cao, Hailin Wang, Yufei He, Hongyang Wang – 2 August 2018 – Methylation of the fifth position of cytosine (5mC) is an important epigenetic modification of DNA. It has been shown that the oxidized derivatives of 5mC, namely 5‐hydroxymethylcytosine (5hmC), 5‐formylcytosine (5fC), and 5‐carboxylcytosine (5caC), are in dynamic existence and have distinct regulatory functions.

Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma

Ronald T. Cotton, Hop S. Tran Cao, Abbas A. Rana, Yvonne H. Sada, David A. Axelrod, John A. Goss, Mark A. Wilson, Steven A. Curley, Nader N. Massarweh – 2 August 2018 – Multidisciplinary hepatocellular carcinoma (HCC) treatment is associated with optimal outcomes. There are few data analyzing the impact of treating hospitals' therapeutic offerings on survival. We performed a retrospective cohort study of patients aged 18‐70 years with HCC in the National Cancer Database (2004‐2012).

Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis

Edward J. Gane, Catherine A. Stedman, Christian Schwabe, Leen Vijgen, Sushmita Chanda, Thomas N. Kakuda, John Fry, Lawrence M. Blatt, Matthew W. McClure – 2 August 2018 – This open‐label, phase IIa study assessed the safety, pharmacokinetics, and efficacy of direct‐acting antiviral agent (DAA) regimens in patients with chronic hepatitis C virus (HCV) infection. Multiple 6‐12‐week oral regimens of 400‐800 mg once daily (QD) AL‐335 + 50 mg QD/every other day odalasvir ± 75‐150 mg QD simeprevir were evaluated in treatment‐naïve, HCV genotype (GT)1/3‐infected patients without cirrhosis.

Subscribe to